jb88 slot If You Own A Samsung Phone, The Galaxy Watch Ultra Is Almost Free This Black Friday

Ennis set to sparkle as 'Christmas in Ennis' program announced

DOGE at Work: Whistleblower Alleges Federal Employee Moved to Florida, Continued to Receive Full D.C. PaycheckRobbie Williams: 'I’ve been a cheeky monkey all my life'

Is Nvidia’s Reign Over? Discover These Under-the-Radar AI Superstars

Short-rested Chiefs, Steelers gear up for Christmas Day clashNavigating Nonprofit Finances in New York City: Expert Accounting SolutionsRobert Anderson chosen for Virginia High School Hall of Fame

Ellen DeGeneres and her wife Portia de Rossi have reportedly left the United States for good, putting their Montecito home up for sale and relocating to the U.K., eager to “get the hell” out of America after Donald Trump’s second presidential win. Multiple reports, notably in The Wrap and TMZ , say that DeGeneres and de Rossi have settled into a new home in the Cotswolds — a region of semi-rural rolling hills and picturesque English villages about two hours southwest of London. TMZ reported that the couple bought their home in the Cotswolds prior to the election, but Trump’s Nov. 5 victory over Kamala Harris left them “disillusioned” about life in America under an incoming Republican administration. The former daytime talk show host and her actor wife became determined to “get the hell out,” a source told TMZ. The Wrap also said that Trump’s victory was a “catalyst” for the couple’s move and said they “plan to never return to the United States.” The Wrap added that DeGeneres also is in need of a “fresh start” for her life and her career. The comedian has been open about being “kicked out of show business” in her recent standup show, after she faced reports in 2022 of presiding over toxic workplace behavior at her syndicated “Ellen” show. DeGeneres was a vocal supporter of Vice President Kamala Harris and donated $3,300 to her campaign, TMZ reported, though she didn’t do campaign appearances for her like her Montecito neighbors, Oprah Winfrey and Katy Perry, did. After Joe Biden decided to not seek re-election and designated Harris as his chosen successor on the Democratic ticket, DeGeneres wrote on social media, “There’s nothing more powerful than a woman whose time has come!! I can’t wait for @KamalaHarris to be our next president.” But just two weeks into Trump’s transition, news has broken that DeGeneres is moving to divest herself of some properties in her extensive Southern California real estate portfolio. Notably, there’s her prime residence, a sprawling Montecito property that she bought in 2019, The Wrap reported. The Wrap said the estate is being offered off market, though it could be listed more broadly soon. A representative for Riskin Partners, the luxury real estate company DeGeneres retains, did not immediately respond to a request for comment Wednesday. While the Daily Beast reported that DeGeneres sold a separate Santa Barbara home a few months earlier for a whopping $96 million, The Wrap said it’s not clear what will happen to her other properties. By moving to the Cotswolds, sometimes known as the “heart of England,” DeGeneres and de Rossi are replicating some of what they had in Montecito — establishing a home in a desirable scenic place about two hours from a major world city. Like Montecito, the Cotswolds has become a popular destination for celebrities to establish country homes. DeGeneres and de Rossi’s new neighbors in the Cotswolds include such A-listers as David and Victoria Beckham, Kate Moss, Patrick Stewart, Elizabeth Hurley and Stella McCartney, the Daily Mail reported . Kate Winslet also had a mansion in the Cotswolds at one point, though it’s unclear if she still lives there, while Hugh Grant has been rumored for years to have a small hideaway in the area. As in Montecito, DeGeneres and de Rossi also would be in proximity to British royalty. In Montecito, they lived near Prince Harry and Meghan Markle, who moved there in 2020 after leaving royal life. Harry and Meghan also briefly leased a home in the Cotswolds after they married in 2018. But in moving to the Cotswolds, the couple’s new royal neighbor would be at the top of the royal line. King Charles III has long had a country home, Highgrove House, in Gloucestershire, one of the counties included in the Cotswolds. In DeGeneres’s recent Netflix standup show, “For Your Approval,” she hinted that she might be ready for the more simple, country pleasures that one can find in the Cotswolds. She joked about how she was spending her time at home in Montecito, after ending her daytime talk show in the walk of the toxic workplace scandal. “I decided to take up gardening,” DeGeneres said. “I got chickens. Let me see what else I can tell you about what’s been going on ... Oh yeah, I got kicked out of show business ... Yeah, the ‘be kind’ girl wasn’t kind. That was the headline.”The best touchless trash cans for modern, mess-free livingDrones, planes or UFOs? Americans abuzz over mysterious New Jersey sightings

NoneEnnis set to sparkle as 'Christmas in Ennis' program announced

Spending squeeze ‘could cost more than 10,000 Civil Service jobs’

O’Malley called to testify in Congress about Social Security remote work policyFREMONT, Calif.--(BUSINESS WIRE)--Dec 23, 2024-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders. Dear Fellow Shareholders: As we conclude 2024 and look forward to 2025, I’d like to take this opportunity to recap some of the important developments this year and share some of our expectations for 2025. Improvements in Commercial Business: Tivic’s Future is in Vagus Nerve Stimulation (VNS) While we continue to improve the performance of our commercial business, some of the most important news this year pertains to our focused entry into Vagus Nerve Stimulation (VNS). VNS has been steadily emerging as a transformative technology in medicine, mostly based on surgically implanted simulators. Polaris Research forecasts that the VNS market will be worth $21B in the next five years, growing at a CAGR of 10.6%. Implanted stimulators have been approved for—or are nearing approval for—treatment of depression, epilepsy, chronic stroke rehabilitation and rheumatoid arthritis in the US and additional conditions overseas. The companies behind these devices are driving both practitioner awareness and adoption and reimbursement pathways. Our strategy is to build on this momentum, focusing on achieving the same or better results using non-invasive stimulation approaches. Our non-invasive cervical approach to VNS (ncVNS) offers a less capital-intensive pathway to market while generating similar biological and clinically meaningful effects. In fact, our non-invasive VNS system has shown best-in-industry effects on outcomes like heart rate variability and achieved “comparable-to” or “better-than” results when compared to invasive implants. In May 2024, we completed a pilot study with Feinstein Institute of Bioelectronic Medicine and demonstrated that our ncVNS approach was able to drive clinically meaningful changes in brain, cardiac, and nervous system activity, consistent with vagus nerve engagement. We are now underway with our second collaborative study that is designed to further optimize ncVNS parameters and their impact on vagus nerve activation. This includes electrode positioning, frequency, and amplitude of stimulation. Results thus far have been positive, increasing confidence as we plan to move into clinical trials with the target populations of medical interest in 2025. These investments to tune the device specifications have both yielded meaningful improvements in efficacy markers and created new intellectual property (IP) that we are protecting on a global scale. The study has been fully enrolled and data from the study will be announced following study completion next year. In parallel with our clinical work, we have worked with seasoned advisors to aggressively evaluate the VNS landscape. This in-depth analysis has involved both primary and secondary research and uncovered targeted opportunities for our ncVNS approach exceeding $30B in annual market opportunity. Today, Tivic has a robust U.S. and international IP portfolio that includes a total of 16 issued patents and 10 pending patents spanning the U.S., Europe, India and China. We expect to continue to grow this base, for broad international protection of our innovations. We are confident that our investment in research and development, combined with a deep understanding of the regulatory processes, commercial drivers and medical needs, will serve us well as we transform Tivic to drive greater degrees of success. Equally as important, we are seeing positive trends in the industry as a whole. Industry awareness of VNS and the accompanying insurance coverage continues to improve. We expect that patient demand for these drug-free therapeutics, supported by appropriate financial access, will accelerate as information about VNS makes its way into mainstream media. VNS and bioelectronic medicine more broadly are expected to play a growing role in the future of healthcare. Looking back at 2024: Company Priorities for 2025 Looking at both the improvements in the base business and the advances we made with vagus nerve stimulation (VNS), we have a lot to be proud of in 2024. I am even more pleased we accomplished all of this while slashing our net operating loss by more than 30%. As we look to 2025, We anticipate that the advancement of our clinical programs for ncVNS will be key to increasing long-term shareholder value. In addition, the board and I continue to evaluate a range of options to maximize shareholder returns, including taking the necessary steps to ensure we regain Nasdaq listing compliance. I would like to recognize the exceptional efforts of the lean and dedicated Tivic Health team. I thank them for their relentless drive and hard work. Together, with our investors, collaborators, and supporters, we are striving to build a company that can transform the future of medicine and make a lasting, positive impact on the lives of people around the world. We are excited about the opportunities that lie ahead, and we look forward to continuing this journey with all of you in 2025. Sincerely, Jennifer Ernst Chief Executive Officer About Tivic Health Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP TM is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP TM is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth Forward-Looking Statements This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumption that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. View source version on businesswire.com : https://www.businesswire.com/news/home/20241223565460/en/ CONTACT: Investor Contact: Hanover International, Inc. ir@tivichealth.com KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES BIOMETRICS NEUROLOGY HEALTH TECHNOLOGY CLINICAL TRIALS BIOTECHNOLOGY SOURCE: Tivic Health Systems, Inc. Copyright Business Wire 2024. PUB: 12/23/2024 04:54 PM/DISC: 12/23/2024 04:54 PM http://www.businesswire.com/news/home/20241223565460/en